Cargando…
Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis
Prostate cancer is an androgen receptor (AR)-driven disease and post-translational modification of AR is critical for AR activation. We previously reported that Arrest-defective protein 1 (ARD1) is an oncoprotein in prostate cancer. It acetylates and activates AR to promote prostate tumorigenesis. H...
Autores principales: | DePaolo, John S., Wang, Zehua, Guo, Jianhui, Zhang, Guanyi, Qian, Chiping, Zhang, Haitao, Zabaleta, Jovanny, Liu, Wanguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342088/ https://www.ncbi.nlm.nih.gov/pubmed/27659526 http://dx.doi.org/10.18632/oncotarget.12163 |
Ejemplares similares
-
ARD1/NAA10 acetylation in prostate cancer
por: Kuhns, Katherine J., et al.
Publicado: (2018) -
Identification of speckle-type POZ protein somatic mutations in African American prostate cancer
por: Buckles, Eric, et al.
Publicado: (2014) -
HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis
por: Albakova, Zarema, et al.
Publicado: (2022) -
Corrigendum: HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis
por: Albakova, Zarema, et al.
Publicado: (2023) -
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors
por: Gillis, Joanna L., et al.
Publicado: (2013)